Okayama, Yusuke
Harada, Naonori http://orcid.org/0000-0001-8585-1450
Makuuchi, Yosuke
Kuno, Masatomo
Takakuwa, Teruhito
Okamura, Hiroshi
Hirose, Asao
Nakamae, Mika
Nishimoto, Mitsutaka
Nakashima, Yasuhiro
Koh, Hideo
Hino, Masayuki
Nakamae, Hirohisa
Article History
Received: 17 July 2023
Revised: 26 December 2023
Accepted: 27 December 2023
First Online: 22 January 2024
Declarations
:
: There are no conflicts of interest related to the submitted work. Dr. Makuuchi, Dr. Kuno, and Dr. Hirose stated no conflicts of interest. Dr. Okayama has received honoraria from Sanofi K.K. Dr. Harada has received honoraria from Chugai Pharmaceutical Co., Ltd., Sanofi K.K., Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., Meiji Seika Pharma Co., Ltd., and Nippon Shinyaku Co., Ltd. Dr. Takakuwa has received honoraria from AbbVie GK, Kyowa Kirin Co., Ltd., Sanofi K.K., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., Bristol-Myers Squibb K.K., and Janssen Pharmaceutical K.K., has received research funding from AbbVie GK, GlaxoSmithKline K.K., Pfizer Japan Inc., and Bristol-Myers Squibb K.K., and has received consulting fees from Sanofi K.K. Dr. Okamura has received honoraria from Nippon Shinyaku Co., Ltd. Dr. Mika Nakamae has received research funding from VERITAS Corporation, and her family received honoraria (see Dr. Hirohisa Nakamaeās honoraria). Dr. Nishimoto has received honoraria from Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., and Nippon Shinyaku Co., Ltd., and has received research funding from Janssen Pharmaceutical K.K., Pfizer Japan Inc., and Astellas Pharma Inc. Dr. Nakashima has received honoraria from Amgen Inc., Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., Bristol-Myers Squibb K.K., and Janssen Pharmaceutical K.K., has received research funding from Astellas Pharma Inc., AbbVie GK, Amgen Inc., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., and Bristol-Myers Squibb K.K., and has received advisory fees from Amgen Inc. and Novartis Pharma K.K. Dr. Koh has received honoraria from Sumitomo Pharma Co., Ltd., MSD K.K., and Novartis Pharma K.K. and has received research funding from Amgen Inc. Dr. Hino has received honoraria from Meiji Seika Pharma Co., Ltd., Astellas Pharma Inc., AbbVie GK, Amgen Inc., Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sanofi K.K., Sumitomo Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., and MSD K.K., has received consulting fees from DAIICHI SANKYO COMPANY, the LIMITED., has received research funding from Nippon Shinyaku Co., Ltd., Pfizer Japan Inc., and Bristol-Myers Squibb K.K., and has received advisory fees from Otsuka Pharmaceutical Co., Ltd. and Kyowa Kirin Co., Ltd., and has donations from JCR Pharmaceuticals Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., DAIICHI SANKYO COMPANY, the LIMITED., Chugai Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., and Sumitomo Pharma Co., Ltd. Dr. Hirohisa Nakamae has received honoraria from Astellas Pharma Inc., Amgen Inc., Otsuka Pharmaceutical Co., Ltd., DAIICHI SANKYO COMPANY, the LIMITED., Sumitomo Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Bristol-Myers Squibb K.K., and Janssen Pharmaceutical K.K., has received advisory fees from Novartis Pharma K.K., and has received research funding from Meiji Seika Pharma Co., Ltd., Novartis Pharma K.K., and Bristol-Myers Squibb K.K. (none of which are related to the submitted work). <i>Authorship statement:</i> Y.O., N.H., M.H., and H.N. conceptualized and designed the study. A.H. and M. Nakamae acquired data. Y.O. and N.H. analyzed the data, interpreted the results, and wrote the manuscript. Y.M., M.K., T.T., H.O., A.H., M. Nakamae, M. Nishimoto, Y.N., H.K., M.H., and H.N. interpreted the results and critically reviewed and revised the manuscript. All authors read and approved the final version of the manuscript.